Biotech Values

[DewDiligence]

ABUS discontinues AB-836 for HBV due_to safety problem:

https://finance.yahoo.com/news/arbutus-presents-ab-729-clinical-200100973.html

As mentioned in our press release dated June 25, 2022, Arbutus decided to dose a new cohort of healthy volunteers for a longer period in the AB-836-001 clinical trial to clarify the earlier safety signal seen in cHBV patients in the same trial. In this healthy volunteer arm, two subjects dosed with AB-836 experienced low grade ALT elevations after more than 20 days of dosing, causing the Company to stop dosing. Based on these additional safety findings, the Company has decided to discontinue clinical development of AB-836.

AB-836 was an HBV capsid inhibitor (a/k/a core inhibitor or CpAM).